Madison Elsaadi
Stock Analyst at B. Riley Securities
(4.64)
# 862
Out of 5,028 analysts
66
Total ratings
50%
Success rate
35.4%
Average return
Main Sectors:
Stocks Rated by Madison Elsaadi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Reiterated: Buy | $11 | $5.95 | +84.87% | 2 | Oct 2, 2026 | |
| ANIK Anika Therapeutics | Initiated Coverage: Buy | $23 | $19.10 | +20.42% | 1 | Sep 18, 2026 | |
| CAPR Capricor Therapeutics | Upgraded: Buy | $5 → $21 | $8.95 | +134.64% | 8 | Sep 14, 2026 | |
| STIM Neuronetics | Initiated Coverage: Buy | $5 | $2.16 | +131.48% | 1 | Sep 11, 2026 | |
| VNDA Vanda Pharmaceuticals | Initiated Coverage: Buy | $17 → $12 | $4.63 | +159.18% | 6 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $17 → $22 | $11.90 | +84.87% | 2 | Aug 6, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $123 | $64.19 | +91.62% | 7 | Aug 5, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $31 → $22 | $3.78 | +482.01% | 15 | Jul 31, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $160 | $45.71 | +250.03% | 1 | Jul 13, 2026 | |
| ETON Eton Pharmaceuticals | Reiterated: Buy | $40 | $55.36 | -27.75% | 14 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.38 | +110.08% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $10 | $4.58 | +118.34% | 2 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $16 | $10.20 | +56.86% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $179 | $179.25 | n/a | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $8.36 | n/a | 1 | Jan 23, 2025 |
Orchestra BioMed Holdings
Oct 2, 2026
Reiterated: Buy
Price Target: $11
Current: $5.95
Upside: +84.87%
Anika Therapeutics
Sep 18, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $19.10
Upside: +20.42%
Capricor Therapeutics
Sep 14, 2026
Upgraded: Buy
Price Target: $5 → $21
Current: $8.95
Upside: +134.64%
Neuronetics
Sep 11, 2026
Initiated Coverage: Buy
Price Target: $5
Current: $2.16
Upside: +131.48%
Vanda Pharmaceuticals
Aug 10, 2026
Initiated Coverage: Buy
Price Target: $17 → $12
Current: $4.63
Upside: +159.18%
COMPASS Pathways
Aug 6, 2026
Reiterated: Buy
Price Target: $17 → $22
Current: $11.90
Upside: +84.87%
Arrowhead Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $123
Current: $64.19
Upside: +91.62%
Wave Life Sciences
Jul 31, 2026
Reiterated: Buy
Price Target: $31 → $22
Current: $3.78
Upside: +482.01%
Spruce Biosciences
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $45.71
Upside: +250.03%
Eton Pharmaceuticals
Jun 25, 2026
Reiterated: Buy
Price Target: $40
Current: $55.36
Upside: -27.75%
May 13, 2026
Reiterated: Buy
Price Target: $5
Current: $2.38
Upside: +110.08%
Apr 30, 2026
Reiterated: Buy
Price Target: $9 → $10
Current: $4.58
Upside: +118.34%
Feb 12, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $10.20
Upside: +56.86%
Oct 1, 2025
Initiated Coverage: Buy
Price Target: $179
Current: $179.25
Upside: n/a
Jan 23, 2025
Reiterated: Buy
Price Target: $11
Current: $8.36
Upside: n/a